VEGFA and Miyoshi myopathy: On the other hand, Yan et al. [105] conducted a multicenter 2:1 randomized, open-label, phase II study involving 114 naïve advanced MM patients receiving chemotherapy (carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 4 weeks) with or without VEGF inhibition (bevacizumab 5 mg/kg every 2 weeks).